UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025

Core Insights - UroGen Pharma Ltd. will report its second quarter 2025 financial results on August 7, 2025, before the stock market opens, followed by a live audio webcast and conference call at 10:00 AM ET [1][2] Company Overview - UroGen Pharma is a biotech company focused on developing and commercializing innovative treatments for urothelial and specialty cancers, emphasizing the need for better patient options [3] - The company has developed RTGel, a proprietary sustained-release hydrogel technology aimed at improving the therapeutic profiles of existing drugs, allowing for longer exposure of urinary tract tissue to medications [3] - UroGen's first product is approved for treating low-grade upper tract urothelial cancer, while its second product is the first FDA-approved treatment for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, both designed for non-surgical tumor ablation [3]